*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# China Health Group Limited
# 中國衛生集團有限公司

*(Carrying on business in Hong Kong as CHG HS Limited)*
*(Incorporated in Bermuda with limited liability)*
(Stock Code: 673)

## VOLUNTARY ANNOUNCMENT

This announcement is made by China Health Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors (the "**Board**") of the Company wishes to announce that on 25 March 2018, the Company, 深圳市北科融匯生命科技有限公司 (Shenzhen Beike Ronghui Life Technology Company Limited*) ("**Beike Ronghui Life Technology**") and 深圳市融匯仁和投資管理有限公司 (Shenzhen Ronghui Renhe Investment Management Company Limited*) ("**Ronghui Renhe Investment Management**") entered into a strategic cooperation agreement (the "**Agreement**"), pursuant to which the parties agreed to cooperate in the following areas: (i) develop research centre for life sciences; (ii) consider the application of life sciences technology in the hospitals managed by the Group; and (iii) explore capital raising opportunities to fund the development of life sciences business.

Beiki Ronghui Life Technology is a joint venture between Shenzhen Beike Biotechnology Co., Ltd. and Ronghui Renhe Investment Management established for the provision of operational and management services for innovative medical and healthcare value chain, spanning from cell storage, biological big data and health management. Ronghui Renhe Investment Management is an investment management company focusing on promoting the combined use of life sciences and artificial intelligence to develop innovative medical and wellness value chain. Currently Ronghui Renhe Investment Management has invested in six medical and healthcare projects in Guizhou, the People's Republic of China. To the best of the Directors' knowledge, information and belief having made all reasonable enquiries, Beike Ronghui Life Technology and Ronghui Renhe Investment Management and their respective ultimate beneficial owners are third parties independent of the Company and its connected persons.

The Group is principally engaged in the provision of hospital management services. The Directors believe the Agreement provides an opportunity for the Group to cooperate with other industry participants to enrich its business scope.

Further announcement(s) will be made by the Company in compliance with the Listing Rules as and when appropriate if there is any transaction materialised under the Agreement.

By Order of the Board
**China Health Group Limited**
**Weng Yu**
*Executive Director*

Hong Kong, 26 March 2018

*As at the date of this announcement, the Board comprises five executive Directors, namely, Mr. Zhang Fan (chairman), Mr. Chung Ho, Mr. Wang Jingming, Mr. Weng Yu and Mr. Wang Yongqing; eight non-executive Directors, namely, Mr. Ying Wei, Mr. Zhang Song, Mr. Xing Yong. Mr. Wang Zili, Mr. Wang Yuexiang, Mr. Li Xuguang, Mr. Ma Zhaorui and Mr. Huang Lianhai; and seven independent non-executive Directors, namely, Mr. Xiao Zuhe, Mr. Wang Qingyou, Mr. Zou Lian, Ms. Yang Huimin, Mr. Xin Hua, Mr. Jiang Xuejun and Mr. Du Yanhua.*